Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro

Author： Desta Zeruesenay   Saussele Tanja   Ward Bryan   Blievernicht Julia   Li Lang   Klein Kathrin   Flockhart David A   Zanger Ulrich M  

Publisher： Future Medicine

ISSN： 1462-2416

Source： Pharmacogenomics, Vol.8, Iss.6, 2007-06, pp. : 547-558

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

The Functional Role of CYP2B6 in Human Drug Metabolism: Substrates and Inhibitors In Vitro, In Vivo and In Silico

By  

Current Drug Metabolism, Vol. 7, Iss. 7, 2006-10 ,pp. : 705-714

Bentham Science Publishers

Access to resources Recommend Favorite

CYP2B6 516TT carriers benefit from efavirenz dose reduction

By  

Inpharma, Vol. 1, Iss. 1609, 2007-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite

Would a CYP2B6 test help HIV patients being treated with efavirenz?

By Sukasem Chonlaphat   Sungkanuparph Somnuek  

Pharmacogenomics, Vol. 14, Iss. 9, 2013-07 ,pp. : 999-1001

Future Medicine

Access to resources Recommend Favorite

In vitro metabolism of the opioid tilidine and interaction of tilidine and nortilidine with CYP3A4, CYP2C19, and CYP2D6

By Weiss Johanna  

Naunyn-Schmiedeberg's Archives of Pharmacology, Vol. 378, Iss. 3, 2008-09 ,pp. : 275-282

Springer Publishing Company

Access to resources Recommend Favorite

Paroxetine metabolism is affected by cytochrome P450 (CYP) 2D6 polymorphism

By  

Inpharma, Vol. 1, Iss. 1468, 2004-01 ,pp. : 19-19

Adis International

Access to resources Recommend Favorite